Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab

Serum neurofilament light as a biomarker in progressive multiple sclerosis

(2020) Raju Kapoor et al.   NEUROLOGY

Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients

(2019) Gloria Dalla Costa et al.   ANNALS OF NEUROLOGY

Neurofilaments as biomarkers in neurological disorders

(2018) Michael Khalil et al.   Nature Reviews Neurology

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa

(2016) Jens Kuhle et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy

(2016) Béatrice Pignolet et al.   NEUROLOGY

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort

(2013) O. Outteryck et al.   EUROPEAN JOURNAL OF NEUROLOGY

L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

(2013) N. Schwab et al.   NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

(2011) Ludwig Kappos et al.   LANCET NEUROLOGY